Multiple Myeloma

Amrita Krishnan, MD, discusses the evolving role of belantamab mafodotin in the treatment of multiple myeloma.

Isatuximab plus VRd induction improved progression-free survival in transplant-eligible, newly diagnosed multiple myeloma.

Suzanne Lentzsch, MD, PhD discusses data for linvoseltamab in patients with relapsed/refractory multiple myeloma

Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma.

Minoo Battiwalla, MD, discusses remaining unmet needs for patients with multiple myeloma and potential strategies being explored to address these needs.

The BCMA/CD19–targeted CAR T-cell therapy GC012F was safe and produced favorable outcomes in newly diagnosed multiple myeloma after induction therapy.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

The FDA approved Darzalex Faspro plus VRd for induction and consolidation in select patients with newly diagnosed multiple myeloma.

Natalia Neparidze, MD, discusses clinical implications and future of belantamab mafodotin and elotuzumab in heavily pretreated, relapsed/refractory multiple myeloma.

Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

The EMA has accepted a marketing authorization application seeking approval of belantamab mafodotin regimens in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD, highlights how therapeutic improvements with quadruplet regimens will benefit all patients with newly diagnosed multiple myeloma.

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD, discusses the use of quadruplet regimens in patients with newly diagnosed multiple myeloma.

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Alfred L. Garfall, MD, MS discusses updated long-term data for teclistamab in patients with relapsed/refractory multiple myeloma.

Amrita Krishnan, MD, discusses the characteristics and factors associated with a higher risk of early relapse for patients with multiple myeloma.

Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.

DREAMM-8 (NCT04484623) is an ongoing, randomized, open-label, phase 3 study evaluating BPd vs PVd in patients with RRMM previously treated with ≥1 line of therapy including lenalidomide.

Noa Biran, MD, discusses avenues for future research and drug development in multiple myeloma.

Mohamad Mohty, MD, PhD, shares the rationale for investigating the real-world efficacy of elranatamab in relapsed/refractory multiple myeloma.